Elutia (ELUT) Q2 2024 earnings summary

Executive summary

• FDA clearance for EluPro, the first drug-eluting biologic envelope, was received in June 2024, with a soft launch in 2H 2024 and full commercial launch expected in January 2025; manufacturing commenced and the facility passed FDA inspection with no deficiencies.

• EluPro targets the $600M pacemaker protection market and an $8B neurostimulation device market, with expanded FDA indications and strong physician interest—88% of surveyed users of a competitor's product indicated intent to switch.

• The company expanded its commercial team and operations leadership, with 26 reps and new executive appointments to support growth.

• Balance sheet strengthened with $13.3M raised in Q2 2024 and $13.8M from warrant exercises in July, bringing pro forma cash to over $30M.

• The company completed the sale of its Orthobiologics Business in November 2023, recognizing a $0.2M gain in Q2 2024.

Financial highlights

• Q2 2024 net sales were $6.3M, nearly flat year-over-year compared to $6.4M in Q2 2023.

• CanGaroo and SimpliDerm net sales each rose 19% and 7% year-over-year to $2.6M; Cardiovascular product sales fell 38% to $1.1M.

• Adjusted gross margin improved to 58% from 56% year-over-year; GAAP gross margin rose to 45% from 43%.

• Net loss widened to $28.2M from $10.6M, mainly due to an $18.3M non-cash warrant revaluation charge; adjusted EBITDA loss improved to $2.9M from $3.4M.

• Cash balance at June 30, 2024, was $18.2M, excluding $13.8M in post-quarter warrant proceeds.

Outlook and guidance

• Full commercial launch of EluPro is set for January 2025, with soft launch and registry data collection underway in 2H 2024.

• Management expects increased sales and marketing expenses in line with revenue growth and continued operating losses and negative cash flows for the foreseeable future.

• Business development and R&D efforts are focused on expanding EluPro into adjacent markets and developing new products.

• The company may seek additional capital through equity offerings, debt financings, or asset sales to address liquidity needs.